Aarti Drugs announced its audited financial results for Q3FY26, demonstrating robust growth in profitability alongside strategic capacity expansion initiatives. The pharmaceutical company's Board of Directors also declared an interim dividend of ₹2 per equity share for FY26.

Q3FY26 Financial Performance

The company delivered strong consolidated financial results for the quarter with significant improvement in profitability metrics. Revenue growth was driven by healthy domestic market traction and exceptional performance in the export formulations segment.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, the company demonstrated consistent growth momentum with strong performance across both revenue and profitability parameters.

Segmental Performance Highlights

The company's diversified business portfolio showed mixed performance across segments, with formulations and specialty chemicals leading growth momentum.

Board Decisions and Corporate Actions

The Board of Directors approved several key decisions during their meeting held on February 3, 2026. The company declared an interim dividend of ₹2 per equity share (20%) for FY26, with February 9, 2026 fixed as the record date for dividend payment.

Manufacturing Expansion and Operational Updates

According to CFO & COO Adhish Patil, the company successfully operationalized key growth projects during the quarter. The backward integration plant in Sayakha for methyl amines achieved 30% capacity utilization in its first quarter of operations, with plans to reach 50% by March or April 2026. The facility currently fulfills 10-15% of captive Metformin requirements, with expectations to achieve 100% self-reliance within 6-8 months.

The Salicylic Acid plant in Tarapur reached a significant milestone, scaling to above 300 tonnes per month. The downstream Salicylates line implementation is expected to transform this segment into a primary value driver for the company.

Senior Management Appointments

The Board approved the inclusion of three functional heads in the list of Senior Management Personnel, effective February 3, 2026:

Aarti Drugs Limited announced that CRISIL Limited has reaffirmed the company's credit ratings on its bank facilities, maintaining confidence in the pharmaceutical manufacturer's financial stability. The rating agency confirmed its assessment of the company's creditworthiness across facilities totaling Rs. 1,768 crores.

Credit Rating Details

CRISIL Limited reaffirmed both long-term and short-term credit ratings for Aarti Drugs Limited's banking facilities. The comprehensive rating covers the company's diverse financing arrangements across multiple banking partners.

Banking Partner Distribution

The rated facilities are distributed across 16 different banking institutions, demonstrating the company's diversified financing approach. Major banking partners include HDFC Bank Limited with facilities worth Rs. 300 crores across cash credit and working capital arrangements, Kotak Mahindra Bank Limited providing Rs. 433.13 crores through term loans and working capital facilities, and Axis Bank Limited contributing Rs. 225 crores in working capital facilities.

Key Banking Relationships

• HDFC Bank Limited: Rs. 300 crores (Cash Credit: Rs. 64 crores, Working Capital: Rs. 236 crores)
• Kotak Mahindra Bank Limited: Rs. 433.13 crores (Term Loan: Rs. 253.13 crores, Working Capital: Rs. 180 crores)
• Axis Bank Limited: Rs. 225 crores (Working Capital Facility)
• Proposed Working Capital Facility: Rs. 124.87 crores

Other significant banking partners include Standard Chartered Bank, Emirates NBD Bank PJSC, The Hongkong and Shanghai Banking Corporation Limited, Sumitomo Mitsui Banking Corporation, State Bank of India, Union Bank of India, RBL Bank Limited, DBS Bank Limited, and IDBI Bank Limited.

Regulatory Compliance

The company communicated this development to BSE Limited and National Stock Exchange of India Limited on January 29, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Rushikesh Deole signed the regulatory filing, ensuring proper disclosure to stakeholders.

The rating letter from CRISIL remains valid until March 31, 2026, with the rating agency maintaining continuous surveillance over the company's facilities. CRISIL noted that any proposed facilities not availed within 180 days from January 29, 2026, would require fresh revalidation.